Liquidata Share/ETF/Trust Analysis
Portfolio Holdings Detail for ISIN IE000NITTFF2
| Stock Name / Fund | iShares Russell 1000 Growth UCITS ETF |
| Issuer | Blackrock |
| Entity holding fund | iShares VII Public Limited Company |
| Entity Type | Umbrella investment company with variable capital and having segregated liability between its funds |
| Entity LEI | 549300Q7FFITMZ2PFZ28 |
| ETF Ticker | R1GR(USD) AS |
| ETF Ticker | R1GR(USD) Euronext Amsterdam |
Holdings detail for HALO
| Stock Name | Halozyme Therapeutics Inc |
| Ticker | HALO(USD) NASDAQ |
| TYPE | Common Stock |
| Country | USA |
| ISIN | US40637H1095 |
| LEI | 529900242I3SV9AGM753 |
Show aggregate HALO holdings
News associated with HALO
- Notable ETF Outflow Detected - XBI, ALNY, HALO, INSM
- Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $119.6 million dollar outflow -- that's a 2.2% decrease week over week - 2025-08-28 11:56:11
- Halozyme Therapeutics, Inc. (NASDAQ:HALO) Receives Consensus Recommendation of “Hold” from Analysts
- Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) has been assigned a consensus rating of “Hold” from the eleven research firms that are covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, five have assigned a hold recommendation and four have issued a buy recommendation on the […] - 2025-08-26 02:16:51
- Halozyme Therapeutics (NASDAQ:HALO) Sets New 52-Week High Following Analyst Upgrade
- Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Tuesday after Morgan Stanley raised their price target on the stock from $75.00 to $80.00. Morgan Stanley currently has an overweight rating on the stock. Halozyme Therapeutics traded as high as $70.70 and last traded at […] - 2025-08-20 02:34:49
- Halozyme Therapeutics, Inc. (NASDAQ:HALO) Position Lessened by Vanguard Group Inc.
- Vanguard Group Inc. trimmed its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 3.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,831,503 shares of the biopharmaceutical company’s stock after selling 450,211 shares during […] - 2025-08-13 05:43:01
- Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Charles Schwab Investment Management Inc.
- Charles Schwab Investment Management Inc. decreased its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 1.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,748,851 shares of the biopharmaceutical company’s stock after selling 34,326 shares during […] - 2025-08-12 05:24:49
- Halozyme Therapeutics (NASDAQ:HALO) Upgraded to “Overweight” at Morgan Stanley
- Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) was upgraded by analysts at Morgan Stanley from an “equal weight” rating to an “overweight” rating in a report released on Wednesday, Marketbeat Ratings reports. The brokerage currently has a $75.00 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $62.00. Morgan Stanley’s […] - 2025-08-08 02:40:46
- Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock Holdings Boosted by LPL Financial LLC
- LPL Financial LLC lifted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 17.1% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 242,432 shares of the biopharmaceutical company’s stock after acquiring an additional 35,429 shares during the period. LPL Financial LLC’s holdings in […] - 2025-08-07 04:46:47
- Halozyme Therapeutics, Inc. (NASDAQ:HALO) Receives $62.70 Consensus Price Target from Analysts
- Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) have earned an average recommendation of “Hold” from the twelve analysts that are presently covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell rating, six have issued a hold rating and four have issued a buy rating on the company. […] - 2025-08-04 02:59:02
- Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Acquired by IFP Advisors Inc
- IFP Advisors Inc increased its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 2,374.1% during the first quarter, HoldingsChannel.com reports. The fund owned 2,103 shares of the biopharmaceutical company’s stock after buying an additional 2,018 shares during the period. IFP Advisors Inc’s holdings in Halozyme Therapeutics were worth $134,000 as of its most […] - 2025-07-29 04:32:50
- Envestnet Asset Management Inc. Acquires 1,161 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)
- Envestnet Asset Management Inc. raised its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 0.4% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 303,774 shares of the biopharmaceutical company’s stock after acquiring an additional 1,161 shares during […] - 2025-07-17 04:50:57
- Teacher Retirement System of Texas Sells 3,278 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)
- Teacher Retirement System of Texas trimmed its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 8.7% in the first quarter, Holdings Channel reports. The institutional investor owned 34,238 shares of the biopharmaceutical company’s stock after selling 3,278 shares during the quarter. Teacher Retirement System of Texas’ holdings in Halozyme Therapeutics were worth $2,185,000 […] - 2025-07-10 05:14:10
- Analysts Set Halozyme Therapeutics, Inc. (NASDAQ:HALO) PT at $61.90
- Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) has received a consensus rating of “Hold” from the twelve research firms that are covering the firm, MarketBeat reports. Two analysts have rated the stock with a sell rating, six have issued a hold rating and four have issued a buy rating on the company. The average […] - 2025-07-10 03:07:07
- Principal Financial Group Inc. Has $24.25 Million Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)
- Principal Financial Group Inc. grew its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 1.0% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 380,021 shares of the biopharmaceutical company’s stock after buying an additional 3,826 shares during the quarter. Principal Financial Group […] - 2025-07-09 05:51:39
- Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Vontobel Holding Ltd.
- Vontobel Holding Ltd. decreased its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 39.9% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 4,742 shares of the biopharmaceutical company’s stock after selling 3,153 shares during the quarter. Vontobel Holding Ltd.’s holdings in Halozyme […] - 2025-07-09 05:00:49
- Envestnet Portfolio Solutions Inc. Has $721,000 Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)
- Envestnet Portfolio Solutions Inc. lowered its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 35.2% in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 11,292 shares of the biopharmaceutical company’s stock after selling 6,143 shares during the period. Envestnet Portfolio Solutions Inc.’s […] - 2025-06-26 04:38:48
- Janney Montgomery Scott LLC Grows Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)
- Janney Montgomery Scott LLC boosted its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 2.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 294,123 shares of the biopharmaceutical company’s stock after purchasing an additional 6,392 shares during […] - 2025-06-19 05:50:56
- SeaCrest Wealth Management LLC Invests $213,000 in Halozyme Therapeutics, Inc. (NASDAQ:HALO)
- SeaCrest Wealth Management LLC purchased a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 3,333 shares of the biopharmaceutical company’s stock, valued at approximately $213,000. Several other institutional […] - 2025-06-09 05:54:51
- Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Wellington Management Group LLP
- Wellington Management Group LLP lessened its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 12.0% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 57,370 shares of the biopharmaceutical company’s stock after selling 7,787 shares during the quarter. Wellington Management Group LLP’s holdings in Halozyme Therapeutics were worth $2,743,000 at the […] - 2025-06-06 05:34:51
- Tidal Investments LLC Has $381,000 Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)
- Tidal Investments LLC trimmed its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 61.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,978 shares of the biopharmaceutical company’s stock after selling 12,598 shares during the period. Tidal Investments LLC’s holdings […] - 2025-05-30 05:47:04
- Friday's ETF with Unusual Volume: GFLW
- The VictoryShares Free Cash Flow Growth ETF is seeing unusually high volume in afternoon trading Friday, with over 2.9 million shares traded versus three month average volume of about 196,000. Shares of GFLW were up about 0.7% on the day.
Components of that ETF with the highes - 2025-05-16 16:18:34
- Baird Financial Group Inc. Buys 221 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)
- Baird Financial Group Inc. raised its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 2.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,119 shares of the biopharmaceutical company’s stock after acquiring an additional 221 shares during the period. […] - 2025-05-16 05:31:14
- Halozyme Therapeutics Reaches Analyst Target Price
- In recent trading, shares of Halozyme Therapeutics Inc (Symbol: HALO) have crossed above the average analyst 12-month target price of $68.12, changing hands for $70.14/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgra - 2025-05-08 09:19:58
- Hsbc Holdings PLC Acquires 3,289 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)
- Hsbc Holdings PLC increased its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 52.0% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 9,615 shares of the biopharmaceutical company’s stock after purchasing an additional 3,289 shares during the quarter. Hsbc […] - 2025-05-08 05:10:47
- Halozyme Therapeutics (NASDAQ:HALO) Sets New 12-Month High After Strong Earnings
- Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report)’s share price reached a new 52-week high during mid-day trading on Wednesday following a stronger than expected earnings report. The company traded as high as $69.07 and last traded at $68.06, with a volume of 1856311 shares trading hands. The stock had previously closed at $59.38. The […] - 2025-05-08 03:08:54
- 4,426 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Acquired by Marshall Wace LLP
- Marshall Wace LLP bought a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) during the 4th quarter, Holdings Channel.com reports. The fund bought 4,426 shares of the biopharmaceutical company’s stock, valued at approximately $212,000. Other institutional investors and hedge funds have also made changes to their positions in the company. Heck […] - 2025-05-06 04:30:49
- Halozyme Files Patent Infringement Lawsuit Against Merck
- (RTTNews) - Halozyme Therapeutics (HALO) filed a patent infringement lawsuit against Merck Sharp & Dohme Corp. in U.S. District Court in New Jersey. Halozyme believes the subcutaneous formulation of Merck's cancer medicine, Keytruda, infringes multiple patents that Halozyme filed - 2025-04-24 10:08:04
- Legal & General Group Plc Decreases Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)
- Legal & General Group Plc lowered its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 1.4% in the fourth quarter, HoldingsChannel.com reports. The fund owned 225,427 shares of the biopharmaceutical company’s stock after selling 3,197 shares during the quarter. Legal & General Group Plc’s holdings in Halozyme Therapeutics were worth $10,778,000 […] - 2025-04-17 06:08:53
- Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by CIBC Private Wealth Group LLC
- CIBC Private Wealth Group LLC lessened its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 99.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,053 shares of the biopharmaceutical company’s stock after selling 963,451 shares during […] - 2025-04-08 05:22:55
- Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by California Public Employees Retirement System
- California Public Employees Retirement System cut its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 6.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 213,687 shares of the biopharmaceutical company’s stock after selling 15,172 shares during the quarter. […] - 2025-04-07 05:56:55
- Schroder Investment Management Group Sells 9,933,836 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)
- Schroder Investment Management Group cut its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 99.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 87,503 shares of the biopharmaceutical company’s stock after selling 9,933,836 shares during the quarter. Schroder Investment Management […] - 2025-04-06 05:30:52
iShares Russell 1000 Growth UCITS ETF HALO holdings
| Date | Number of HALO Shares Held | Base Market Value of HALO Shares | Local Market Value of HALO Shares | Change in HALO Shares Held | Change in HALO Base Value | Current Price per HALO Share Held | Previous Price per HALO Share Held |
|---|
| 2025-09-18 (Thursday) | 1,809 | USD 138,714 | USD 138,714 | 0 | USD 1,574 | USD 76.6799 | USD 75.8098 |
| 2025-09-17 (Wednesday) | 1,809 | USD 137,140 | USD 137,140 | 0 | USD -73 | USD 75.8098 | USD 75.8502 |
| 2025-09-16 (Tuesday) | 1,809 | USD 137,213 | USD 137,213 | 0 | USD -868 | USD 75.8502 | USD 76.33 |
| 2025-09-15 (Monday) | 1,809 | USD 138,081 | USD 138,081 | | | | |
| 2025-09-12 (Friday) | 1,809 | USD 139,112 | USD 139,112 | | | | |
| 2025-09-11 (Thursday) | 1,809 | USD 140,252 | USD 140,252 | 0 | USD 3,130 | USD 77.5301 | USD 75.7999 |
| 2025-09-10 (Wednesday) | 1,809 | USD 137,122 | USD 137,122 | 0 | USD -489 | USD 75.7999 | USD 76.0702 |
| 2025-09-09 (Tuesday) | 1,809 | USD 137,611 | USD 137,611 | 0 | USD 398 | USD 76.0702 | USD 75.8502 |
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdingsShare Trades of HALO by Blackrock for IE000NITTFF2
Show aggregate share trades of HALO| Date | Action | Quantity | Market High | Market Low | Likely Trade Price | Likely Trade Value (Profit/Loss) | Average Price previous trades |
|---|
| 2025-08-20 | BUY | 18 | | | 71.130* | | 57.45 |
| 2025-08-18 | BUY | 54 | | | 68.960* | | 55.61 |
| 2025-07-18 | BUY | 19 | | | 56.450* | | 55.50 |
| 2025-07-09 | SELL | -36 | | | 56.580* | | 53.98 Profit of 1,943 on sale |
| 2025-07-08 | BUY | 36 | | | 55.800* | | 53.62 |
| 2025-07-02 | BUY | 72 | | | 53.840* | | 52.02 |
Market high and low price is on the date. * (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection
The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close
Shorting History of HALO
| Date | Shorted Volume | Short Exempt Volume | Total Shares Traded | % Shorted |
|---|
| 2025-09-19 | 371,468 | 246 | 613,712 | 60.5% |
| 2025-09-18 | 369,209 | 50 | 726,194 | 50.8% |
| 2025-09-17 | 256,611 | 9,792 | 553,701 | 46.3% |
| 2025-09-16 | 228,403 | 90 | 394,052 | 58.0% |
| 2025-09-15 | 227,697 | 268 | 471,461 | 48.3% |
| 2025-09-12 | 221,090 | 110 | 427,510 | 51.7% |
| 2025-09-11 | 514,076 | 1,959 | 993,633 | 51.7% |
| 2025-09-10 | 166,289 | 386 | 439,002 | 37.9% |
| 2025-09-09 | 273,054 | 401 | 595,146 | 45.9% |
| 2025-09-08 | 673,482 | 7,545 | 952,324 | 70.7% |
| 2025-09-05 | 290,024 | 13,523 | 686,839 | 42.2% |
| 2025-09-04 | 407,737 | 5,358 | 712,769 | 57.2% |
| 2025-09-03 | 550,404 | 13,706 | 1,063,453 | 51.8% |
| 2025-09-02 | 616,278 | 11,835 | 991,442 | 62.2% |
| 2025-08-29 | 269,930 | 76,054 | 395,068 | 68.3% |
| 2025-08-28 | 433,760 | 4,556 | 628,921 | 69.0% |
| 2025-08-27 | 1,260,611 | 4,539 | 1,702,449 | 74.0% |
| 2025-08-26 | 588,702 | 2,967 | 980,200 | 60.1% |
| 2025-08-25 | 371,565 | 2,132 | 648,270 | 57.3% |
| 2025-08-22 | 876,545 | 177,507 | 1,274,834 | 68.8% |
| 2025-08-21 | 443,688 | 60,024 | 724,496 | 61.2% |
| 2025-08-20 | 591,075 | 169,034 | 869,550 | 68.0% |
| 2025-08-19 | 935,006 | 12,421 | 1,715,495 | 54.5% |
| 2025-08-18 | 449,801 | 7,338 | 718,194 | 62.6% |
| 2025-08-15 | 329,469 | 7,019 | 525,006 | 62.8% |
| 2025-08-14 | 516,843 | 66,827 | 759,578 | 68.0% |
| 2025-08-13 | 389,927 | 5,826 | 908,606 | 42.9% |
| 2025-08-12 | 781,374 | 13,603 | 1,175,102 | 66.5% |
| 2025-08-11 | 586,472 | 59,410 | 817,358 | 71.8% |
| 2025-08-08 | 285,728 | 19,152 | 668,999 | 42.7% |
| 2025-08-07 | 408,493 | 14 | 863,233 | 47.3% |
| 2025-08-06 | 1,204,156 | 4,850 | 2,539,387 | 47.4% |
| 2025-08-05 | 583,045 | 290 | 1,069,043 | 54.5% |
| 2025-08-04 | 177,608 | 200 | 363,851 | 48.8% |
| 2025-08-01 | 207,308 | 307 | 616,187 | 33.6% |
| 2025-07-31 | 622,123 | 147 | 1,098,496 | 56.6% |
| 2025-07-30 | 274,323 | 1,375 | 540,028 | 50.8% |
| 2025-07-29 | 318,079 | 3,010 | 584,122 | 54.5% |
| 2025-07-28 | 194,988 | 129 | 416,263 | 46.8% |
| 2025-07-25 | 115,024 | 0 | 312,074 | 36.9% |
| 2025-07-24 | 144,854 | 26,732 | 266,453 | 54.4% |
| 2025-07-23 | 154,871 | 30,676 | 443,144 | 34.9% |
| 2025-07-22 | 203,247 | 0 | 381,321 | 53.3% |
| 2025-07-21 | 144,964 | 1,656 | 318,072 | 45.6% |
| 2025-07-18 | 136,030 | 1,809 | 379,301 | 35.9% |
The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.
Back to Listing
Disclaimer
All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.